Drug intelligence / Profile preview

TLM-005

Development stage: Unknown
Lead developer: Tsubota Laboratory

Overview

TLM-005 is an investigational Therillume pipeline asset being developed for glioblastoma multiforme. Publicly available pipeline information identifies it only by the internal code name TLM-005 and places it in Phase 1 development for GBM, with annotations indicating that it has completed at least a Phase Ib clinical trial in GBM. No validated public details were found on its molecular target, modality, route of administration, formulation, or precise mechanism of action, so it should currently be treated as an undisclosed early-stage oncology candidate from Therillume.

Beyond the preview

Go deeper on TLM-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLM-005.

Explore the full profile